Vnitr̆ní lékar̆ství
-
Vnitr̆ní lékar̆ství · May 2002
[Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
Several prospective randomized studies have shown that the treatment of chronic myeloid leukemia with interferon alfa (IFN alpha) prolongs the survival by comparison with conventional chemotherapy. However, long-term treatment with Interferon alfa (IFN alpha) can produce or exacerbate immune-mediated complications (IMC). The purpose of this study was to analyze the experience with IMC in patients with chronic myelogenous leukemia (CML) undergoing IFN alpha treatment. ⋯ The frequency of IMC of clinical relevance with interferon alfa therapy in CML increased (long-term therapy). The patients treated with interferon alfa should be monitored for sign and symptoms of autoimmunity.